

January 18, 2024

Corporate Relationship Department  
BSE Limited, PJ Towers, Dalal Street,  
Mumbai- 400001

Dear Sirs

**Sub: Unaudited Financial Results and Limited Review Report for the quarter and nine months ended December 31, 2023- Outcome of the Board meeting**

**Ref: 1) Regulation 33 of SEBI (LODR) Regulations 2015**

**2) Script Code: 526783**

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that, in terms of Regulation 30, 33 and other applicable provisions of Listing Regulations, the Board of Directors of the Company at its meeting held on January 18, 2024 commenced at 03:30 PM and concluded at 04:00 PM have inter alia approved the Un-audited financial results of the Company for the quarter and nine months ended December 31, 2023.

- 1) Copies of the Un-audited Financial Results and Limited Review Report issued by the Statutory Auditors of the Company for the quarter and nine months ended December 31, 2023 is enclosed.
- 2) The Company has made arrangement for release of the Un-audited Financial results for the quarter and nine months ended December 31, 2023 in the newspaper as per the requirement of the Listing Regulations.

Kindly take the above information on record.

Thanking you,

Yours faithfully

For **DR. AGARWAL'S EYE HOSPITAL LIMITED**



**MEENAKSHI JAYARAMAN**  
**COMPANY SECRETARY**





Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Grems Road, Chennai - 600 006  
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in Rs. Crores except earnings per share data)

## Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31st December 2023

S.No.	Particulars	Quarter Ended			Nine months ended		Year ended
		31-Dec-23 Unaudited	30-Sep-23 Unaudited	31-Dec-22 Unaudited	31-Dec-23 Unaudited	31-Dec-22 Unaudited	31-Mar-23 Audited
1	<b>Income</b>						
	(a) Revenue from Operations	75.67	83.27	63.54	236.74	198.68	267.89
	(b) Other Income	0.95	2.29	0.19	4.35	1.15	1.76
	<b>Total Income</b>	<b>76.62</b>	<b>85.56</b>	<b>63.73</b>	<b>241.09</b>	<b>199.83</b>	<b>269.65</b>
2	<b>Expenses</b>						
	(a) Purchase of Stock-in-Trade	8.68	9.93	7.71	27.10	23.12	30.68
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	(0.62)	(0.44)	(0.48)	(1.69)	(1.27)	(0.87)
	(c) Surgical Lens including other consumables	9.55	9.72	6.94	27.84	23.17	31.15
	(d) Consultancy Charges	11.94	13.50	9.77	36.65	28.72	38.55
	(e) Employee Benefit Expenses	15.51	16.43	13.49	48.37	39.24	53.26
	(f) Finance Costs	1.83	1.69	1.74	5.14	5.06	6.87
	(g) Depreciation and Amortisation Expense	6.89	6.34	7.10	19.08	18.64	20.18
	(h) Other Expenses	10.12	11.74	10.76	33.69	31.93	40.43
	<b>Total Expenses</b>	<b>63.90</b>	<b>68.91</b>	<b>57.03</b>	<b>196.18</b>	<b>168.61</b>	<b>220.25</b>
3	<b>Profit before Tax (1-2)</b>	<b>12.72</b>	<b>16.65</b>	<b>6.70</b>	<b>44.91</b>	<b>31.22</b>	<b>49.40</b>
4	<b>Tax Expense</b>						
	- Current Tax	3.38	3.97	2.00	11.52	8.82	12.33
	- Deferred Tax	(0.10)	0.09	(0.36)	(0.18)	(0.84)	0.15
5	<b>Net Profit after tax for the period (3-4)</b>	<b>9.44</b>	<b>12.59</b>	<b>5.06</b>	<b>33.57</b>	<b>23.24</b>	<b>36.92</b>
6	<b>Other Comprehensive Income</b>						
	(a) Items that will not be reclassified to the Statement of Profit and Loss						
	- Actuarial (loss) / gain on defined benefit obligation	(0.33)	(0.53)	(0.07)	(0.98)	(0.50)	(0.48)
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	0.09	0.14	0.02	0.26	0.13	0.13
	<b>Total Other Comprehensive income / (loss) (net of tax)</b>	<b>(0.24)</b>	<b>(0.39)</b>	<b>(0.05)</b>	<b>(0.72)</b>	<b>(0.37)</b>	<b>(0.35)</b>
7	<b>Total Comprehensive Income (5+6)</b>	<b>9.20</b>	<b>12.20</b>	<b>5.01</b>	<b>32.85</b>	<b>22.87</b>	<b>36.57</b>
8	<b>Paid-up equity share capital (Face value Rs.10/- each)</b>	<b>4.70</b>	<b>4.70</b>	<b>4.70</b>	<b>4.70</b>	<b>4.70</b>	<b>4.70</b>
9	<b>Reserves (Other Equity)</b>						<b>108.64</b>
10	<b>Earnings Per Equity Share (EPS) (Face value of Rs.10/- each)</b>						
	(a) Basic	20.09	26.79	10.77	71.43	49.45	78.55
	(b) Diluted	20.09	26.79	10.77	71.43	49.45	78.55
		(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

## Notes:

- The above unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') notified under Section 133 of the Companies Act, 2013, read together with the Companies (Indian Accounting Standards) Rules, 2013 (as amended).
- The above unaudited financial results for the quarter and nine months ended 31st December 2023 have been reviewed by the Audit Committee and the same has been approved and taken on record by the Board of Directors at their meeting held on 18th January 2024. The above results for the quarter and nine months ended 31 December 2023 has also been subjected to limited review by the Statutory Auditors of the Company.
- The Company operates in a single segment i.e. "Eye Care related sales and services" and hence, does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.

Place : Beeston, United Kingdom  
Date : 18th January 2024

By order of the Board

Dr. Amar Agarwal  
Chairman & Managing Director  
DIN No. 00435584

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



*R. Prasanna Venkatesh*

**R. Prasanna Venkatesh**  
(Partner)  
(Membership No. 214045)

Place: Chennai  
Date: January 18, 2024  
UDIN: 24214045BKEKJL2540



Dr. Agarwal's Eye Hospital Limited  
CIN : 185110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006  
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in Rs. Crores except earnings per share data)

Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31st December 2023

Particulars	Quarter Ended		Nine months ended		Year Ended
	31-Dec-23 Unaudited	31-Dec-22 Unaudited	31-Dec-23 Unaudited	31-Dec-22 Unaudited	31-Mar-23 Audited
Revenue from Operations	75.67	63.54	236.74	198.68	267.89
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	12.72	6.70	44.91	31.22	49.40
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	12.72	6.70	44.91	31.22	49.40
Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	9.44	5.06	33.57	23.24	36.92
Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	9.20	5.01	32.85	22.87	36.57
Paid-up Equity Share Capital (Face Value of Rs.10/- each)	4.70	4.70	4.70	4.70	4.70
Reserves (Other Equity)	-	-	-	-	108.64
Earnings Per Share (for continuing and discontinued operations) (Face Value of Rs. 10/- each):					
(a) Basic	20.09	10.77	71.43	49.45	78.55
(b) Diluted	20.09	10.77	71.43	49.45	78.55
	(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

Notes:

1) The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Unaudited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com).

Place : Beeston, United Kingdom  
Date : 18th January 2024

By order of the Board

Dr. Amar Agarwal  
Chairman & Managing Director  
DIN No. 00435684

